Syndecan-1

Syndecan-1

Syndecan-1 Molekülinformation

Molecule Name
Syndecan-1
Molekülalias
SDC1,Syndecan-1,CD138,SYND1,SDC
Drug Development Progress
Anzahl der klinischen Arzneimittel2
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 1 Clinical
Target-Alias
Syndecan Proteoglycan 1,CD138 Antigen,SYND1,SDC,Heparan Sulfate Proteoglycan Fibroblast Growth Factor Receptor,Syndecan,CD138,Syndecan-1,SDC1,Syndecan 1
Molekülhintergrund
Syndecan-1 (SYND1 or SDC1) is also known as CD antigen CD138, is a transmembrane (type I) heparan sulfate proteoglycan and is a member of the syndecan proteoglycan family. The syndecans mediate cell binding, cell signaling, and cytoskeletal organization and syndecan receptors are required for internalization of the HIV-1 tat protein. The syndecan-1 / SDC1 protein functions as an integral membrane protein and participates in cell proliferation, cell migration and cell-matrix interactions via its receptor for extracellular matrix proteins. It is a useful marker for plasma cells, but only if the cells tested are already known to be derived from blood.

Syndecan-1 Produktliste

Species
  • Human(5)
Tag
  • His Tag(2)
  • Fc Tag(1)
  • Fc Tag & Avi Tag(1)
  • His Tag & Avi Tag(1)
Host
  • HEK293(5)
Conjugate
  • Biotin-labeled(2)
  • Unconjugated(2)
  • FITC Labeled(1)
Grade
  • RUO(5)
Low Endotoxin
  • No(5)
MoleculeCat. No.Product NameArtHostStructurePurityActivitySize&PriceAdd to Cart
Syndecan-1
Human Syndecan-1 Protein, Fc Tag
Human
HEK293
SDS-PAGE
ELISAFlow

$360.00

100ug
Syndecan-1
HOTAvitag
SY1-H82F3
Biotinylated Human Syndecan-1 Protein, Fc,Avitag™
Human
HEK293
SDS-PAGE
ELISAFlow

$360.00

25ug
Syndecan-1
Human Syndecan-1 Protein, His Tag
Human
HEK293
SDS-PAGE
ELISAFlow

$360.00

100ug
Syndecan-1
HOTAvitag
SY1-H82E2
Biotinylated Human Syndecan-1 Protein, His,Avitag™
Human
HEK293
SDS-PAGE
ELISAFlow

$360.00

25ug
Syndecan-1
FITC-Labeled Human Syndecan-1 Protein, His Tag
Human
HEK293
SDS-PAGE
ELISAFlow

$330.00

25ug
You Have Viewed 1-5 Of 5 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
ATLCAR.CD138 (UNC Lineberger Comprehensive Cancer Center)Phase 1 ClinicalUnc Lineberger Comprehensive Cancer Center
Immune System Diseases; Multiple Myeloma
Details
QXL-138AMQXL-138AMPhase 1 ClinicalNammi Therapeutics Inc
Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Gastrointestinal Neoplasms; Lung Neoplasms; Multiple Myeloma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours
Details
Customer Reviews